Kynam Capital reports 4.01% stake in Vera Therapeutics
Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of Vera Therapeutics, Inc. Class A common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of Vera Therapeutics, Inc. Class A common stock. They have shared voting and dispositive power over 2,890,059 shares, representing 4.01% of the class, and state ownership of 5 percent or less of the class.
Key Figures
Key Terms
beneficially owned financial
Ownership of 5 percent or less of a class financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Vera Therapeutics (VERA) does Kynam Capital report in this Schedule 13G/A?
Who are the reporting persons in the Vera Therapeutics (VERA) Schedule 13G/A?
What level of voting power does Kynam Capital have in Vera Therapeutics (VERA)?
Does Kynam Capital still own 5% or more of Vera Therapeutics (VERA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.